PRX-102 Shows Safety, Efficacy Similar to Fabrazyme in Phase 3 Trial

PRX-102 Shows Safety, Efficacy Similar to Fabrazyme in Phase 3 Trial

324870

PRX-102 Shows Safety, Efficacy Similar to Fabrazyme in Phase 3 Trial

Two years of treatment with the experimental enzyme replacement therapy PRX-102 (pegunigalsidase alfa) prevented kidney decline in adults with Fabry disease and showed safety and effectiveness similar to Fabrazyme (agalsidase beta), top-line data from the BALANCE Phase 3 clinical trial show. In addition to meeting the trial’s primary goal in kidney health, the therapy, developed by Protalix BioTherapeutics in collaboration with Chiesi Global Rare Diseases, was reported to be well-tolerated and to show a favorable immune…

You must be logged in to read/download the full post.